Autism Spectrum Disorder

The Alzheimer’s, Autism, Cognitive Impairment Stem Cell Treatment Study (ACIST) is an IRB-approved and NIH-registered clinical study (NCT 3724136) investigating the use of autologous (patient-derived) bone marrow-derived stem cells (BMSCs) for the treatment of Autism Spectrum Disorder (ASD) in adults aged 18 and older.

A growing body of preclinical and clinical research suggests that BMSCs may hold therapeutic potential for a range of neurological conditions. Notably, a university-led study at Duke University Medical Center—Autologous Umbilical Cord Blood Infusion for Children with Autism Spectrum Disorder—has added to the scientific foundation for exploring cell-based therapies in ASD.

It is important to emphasize that participation in the ACIST study is not intended to replace conventional medical care. All participants should have completed standard treatment protocols prior to enrolling in the study, ensuring that this investigational approach is considered within the broader context of comprehensive patient care.